Despite positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from PBMs. The companies are frequently building limitations to coverage, including steep price requirements and prior authorization that restrict user availability. Market suggest that th